🔎 Trials Near Me

Home › Kanser sa Baga › Michigan

Pag-aaral pangklinika para sa Kanser sa Baga sa Michigan

45 pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa mga site sa Michigan.

Mga Lungsod sa Michigan

Opisyal na teksto ng pag-aaral (English)

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • University of Michigan Rogel Cancer Center, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • at 37 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • at 50 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04267848

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Corewell Health - Butterworth Hospital, Grand Rapids
  • Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
  • Corewell Health - Research Specimen Processing Area, Grand Rapids
  • at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06758401

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • at 27 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04181060

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • at 20 pa
Nagre-recruitPhase 3
Edad 70 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06096844

A Registry for People With Lung Cancer

  • University of Michigan (Data Collection Only), Ann Arbor
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06424327

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  • Local Institution - 0418, Ann Arbor
  • Local Institution - 0405, Detroit
  • Local Institution - 0420, Traverse City
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07063745

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • START Midwest, Grand Rapids
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06128551

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  • University of Michigan Medical School Rogel Cancer Center, Ann Arbor
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07629960

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  • START Midwest, Grand Rapids
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07349537

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT05786924

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Karmanos Cancer Institute, Detroit
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04585750

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Karmanos Cancer Institiute, Detroit
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT06293898

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of Michigan, Ann Arbor
  • The Cancer & Hematology Centers, Grand Rapids
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06119581

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT06400472

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • Henry Ford Cancer - Detroit, Detroit
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06343402

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • at 71 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05334069

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Henry Ford Cancer Institute-Downriver, Brownstown
  • Henry Ford Health Center - Brownstown, Brownstown
  • Henry Ford Health Center - Chesterfield, Chesterfield
  • at 13 pa
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 45 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06995898

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Karmanos Cancer Institute, Detroit
  • Henry Ford Health, Detroit
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT06881784

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

  • University of Michigan, Ann Arbor
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT07499674

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Weisberg Cancer Treatment Center, Farmington Hills
  • McLaren Cancer Institute-Flint, Flint
  • at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06500481

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • McLaren Cancer Institute-Bay City, Bay City
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • at 41 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05624996

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Karmanos Cancer Institute, Detroit
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT05592626

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • START - Midwest, Grand Rapids
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT07444814

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Henry Ford Cancer Institute, Detroit
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT04198766

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

  • Henry Ford Cancer- Detroit, Detroit
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07339059

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06162221

Prediction Augmented Screening Initiative

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Nagre-recruit
Edad 50 hanggang 80 · Lahat ng kasarian · Na-update Hun 26, 2026 · NCT06538636

Gilteritinib for the Treatment of ALK NSCLC

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 26, 2026 · NCT06225427

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • Karmanos Cancer Institute, Detroit
Nagre-recruitPhase 2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Hun 26, 2026 · NCT04614103

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • at 19 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT05642572

A Study of ZW251 in Participants With Advanced Solid Tumors

  • START Midwest, Grand Rapids
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update May 7, 2026 · NCT07164313

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • at 14 pa
Nagre-recruitPhase 2
18 Minutes · Lahat ng kasarian · Na-update May 5, 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
  • at 7 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT06616584

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • University of Michigan, Ann Arbor
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 22, 2026 · NCT07020221

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • Karmanos Cancer Institute, Detroit
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 18, 2026 · NCT06244771

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 19, 2026 · NCT02984761

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 27, 2026 · NCT05467748

Mula sa ClinicalTrials.gov, na-kuha noong Set 29, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.